Zhou Qing, Tan Deming, Yi Zhaoquan, Zheng Yixiang, Lu Menghou
Department of Infectious Diseases, Zhuzhou Central Hospital, Zhuzhou Hunan,China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Apr;38(4):388-94. doi: 10.3969/j.issn.1672-7347.2013.04.009.
To evaluate the mid-term prognostic value of procalcitonin (PCT), endotoxin and common inflammatory markers combining the model for end-stage liver disease (MELD) score in patients with chronic severe hepatitis.
A total of 124 chronic severe hepatitis patients were enrolled, who were hospitalized in the Department of Infectious Diseases, Xiangya Hospital, Central South University from May 2011 to December 2011. Indexes of inflammation, liver and kidney function tests and MELD were determined within 24 h after the admission, and blood samples were collected for measurement of endotoxin , procalcitonin (PCT), and C-reactin protein (CRP). The outcome was confirmed after discharge follow-up at the end of the 3rd month. According to the outcome, the 124 patients were divided into a survival group (n=58) and a death group(n=66).
Endotoxin and common inflammatory markers (WBC, PMN, and CRP) are not reliable indicators to predict the prognosis in patients with chronic-severe hepatitis. MELD score is significantly correlated with the outcome of mid-term chronic severe hepatitis, PCT and age are both positively correlated with the MELD score. PCT and age combining MELD score can be used to predict the 3 month mid-term mortality of chronic severe hepatitis. MELD score has better prognostic value than PCT. MELD score combining PCT can improve the specificity of prediction.
评估降钙素原(PCT)、内毒素及常见炎症标志物联合终末期肝病模型(MELD)评分对慢性重型肝炎患者的中期预后价值。
选取2011年5月至2011年12月在中南大学湘雅医院感染科住院的124例慢性重型肝炎患者。入院后24小时内测定炎症指标、肝肾功能及MELD评分,并采集血样检测内毒素、降钙素原(PCT)及C反应蛋白(CRP)。在第3个月末出院随访后确定结局。根据结局将124例患者分为生存组(n = 58)和死亡组(n = 66)。
1)124例患者中,66例死亡,58例存活,单因素分析显示两组在年龄、MELD评分、白细胞(WBC)、中性粒细胞(PMN)、CRP及PCT方面存在统计学差异(P < 0.05)。二元logistic回归分析表明年龄、MELD评分及PCT与结局高度相关(OR分别为1.07、1.42和1.02,P < 0.05),可用于预测慢性重型肝炎3个月的中期死亡率。2)MELD评分与中期死亡率显著相关。年龄与MELD评分呈正相关,Pearson相关系数为0.21(P < 0.05)。PCT也与MELD呈正相关,Spearman相关系数为0.54(P < 0.01)。3)根据受试者工作特征(ROC)曲线分析,MELD评分和PCT的曲线下面积(AUC)分别为0.91和0.77,高于其他指标(P < 0.01)。当MELD评分达到30.09及以上时,这些受试患者的预测死亡风险最高(82.26%)。PCT联合MELD评分预测的死亡风险低于单独使用MELD评分(75.00%),但MELD评分联合PCT的特异性为100%,阳性预测值为1.00。
内毒素及常见炎症标志物(WBC、PMN和CRP)不是预测慢性重型肝炎患者预后的可靠指标。MELD评分与慢性重型肝炎中期结局显著相关,PCT和年龄均与MELD评分呈正相关。PCT和年龄联合MELD评分可用于预测慢性重型肝炎3个月的中期死亡率。MELD评分比PCT具有更好的预后价值。MELD评分联合PCT可提高预测的特异性。